Clinical Trial Update: Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis

View source ↗

Summary

This completed clinical trial examined whether NAT2 and CYP2E1 genetic variants influence the risk of antituberculosis therapy–induced hepatitis in patients wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• ISONIAZID (ISONIAZID)
• Rifampicin

Snippet

Sponsor: Maulana Azad Medical College | Conditions: Pulmonary Tuberculosis | Status: COMPLETED